Cardiology
RSSArticles
-
New antithrombotic guidelines
-
Continuing warfarin for surgery
-
NSAIDs associated with less vascular risk
-
Preventing ICU Infections: An Effective Application of An Old Public Health Strategy
Despite better compliance with hand hygiene and screening, use of isolation, and other techniques, ICUs remain notorious breeding grounds for hospital-acquired infections. A universal decolonization strategy reduces the total number of ICU bloodborne infections. -
‘It’s the Worst Headache of My Life:’ Subarachnoid Hemorrhage — A Brief Review
Subarachnoid hemorrhage (SAH) is a stroke syndrome, defined as rapidly developing neurological dysfunction and/or headache because of bleeding into the subarachnoid space (the space between the subarachnoid membrane and the pia mater of the brain or spinal cord), which is not caused by trauma.1 It is a dire condition with high morbidity and mortality. -
Pharmacology Watch: Is Naproxen the Safest NSAID for the Heart?
NSAIDs and cardiovascular risk; new antithrombotic guidelines; warfarin during surgery; Pfizer selling Viagra online; azithromycin and cardiovascular risk; and FDA actions. -
Clinical Briefs in Primary Care Supplement
-
Continuous EEG During Therapeutic Hypothermia After Cardiac Arrest — Is it Useful?
Moderate or severe EEG abnormalities are frequently seen in patients during therapeutic hypothermia following cardiac arrest and these findings are associated with poor outcomes. -
Critical Care Alert - Full July 2013 Issue in PDF
-
Pharmacology Update
The fda has approved a higher dose of the rivastigmine transdermal system (13.3 mg/24 hours) for the treatment of Alzheimer's disease (AD). Lower-dose patches were previously approved for mild-to-moderate disease. Rivastigamine is a reversible acetylcholinesterase inhibitor. The transdermal system is marketed by Novartis as Exelon.